



DEC 05 2006

Application No. (if known): 10/089,641

Attorney Docket No.: 06181/000K439-US0

## **Certificate of Express Mailing Under 37 CFR 1.10**

I hereby certify that this correspondence is being deposited with the United States Postal Service as Express Mail, Airbill No. in an envelope addressed to:

EV834730 500 - US

MS AF  
Commissioner for Patents  
P.O. Box 1450  
Alexandria, VA 22313-1450

on December 5, 2006  
Date

**Signature**

Typed or printed name of person signing Certificate

**Registration Number, if applicable**

**Telephone Number**

**Note:** Each paper must have its own certificate of mailing, or this certificate must identify each submitted paper.

Fee Transmittal (1 page)  
Inventors' Declaration Under 37 CFR §1.67 (a) (5 pages)  
Copy of Notice to Comply (1 page)  
Amendment Transmittal (1 page)  
Amendment After Final Action Under 37 C.F.R. 1.116 (4 pages)  
One Month Request for Extension of Time (1 page)  
Amendment to Sequence Listing (2 pages)  
Paper Copy of Substitute Sequence Listing (2 pages)  
Diskette of Substitute Sequence Listing (1 disk)  
Check in the amount of \$120.00  
Postcard



12-07-06

AF  
JKW

## AMENDMENT TRANSMITTAL LETTER

Docket No.  
06181/000K439-US0Application No.  
10/089,641-Conf. #3102Filing Date  
May 3, 2002Examiner  
B. A. WhitemanArt Unit  
1635

Applicant(s): Dae-Gun Kim et al.

Invention: EXPRESSION VECTOR CODING P972-GENE FOR CANCER THERAPY AND  
ADENOVIRUS PRODUCING THE SAME

## TO THE COMMISSIONER FOR PATENTS

Transmitted herewith is an amendment in the above-identified application.

The fee has been calculated and is transmitted as shown below.

CLAIMS AS AMENDED					
	Claims Remaining After Amendment	Highest Number Previously Paid	Number Extra Claims Present	Rate	
Total Claims	15	- 47 =	0	x 50.00	0.00
Independent Claims	4	- 6 =	0	x 200.00	0.00
Multiple Dependent Claims (check if applicable) <input type="checkbox"/>					
Other fee (please specify): Extension for response within first month					120.00
TOTAL ADDITIONAL FEE FOR THIS AMENDMENT:					120.00

 Large Entity Small Entity No additional fee is required for this amendment. Please charge Deposit Account No. 04-0100 in the amount of \$ \_\_\_\_\_  
A duplicate copy of this sheet is enclosed. A check in the amount of \$ 120.00 to cover the filing fee is enclosed. Payment by credit card. Form PTO-2038 is attached. The Director is hereby authorized to charge and credit Deposit Account No. 04-0100  
as described below. A duplicate copy of this sheet is enclosed. Credit any overpayment. Charge any additional filing or application processing fees required under 37 CFR 1.16 and 1.17.  
Shelly M. Fujikawa  
Attorney/Agent Reg. No.: 56,190

Dated: December 5, 2006

DARBY & DARBY P.C.  
P.O. Box 5257  
New York, New York 10150-5257  
(212) 527-7700



<b>Notice to Comply</b>	Application No. 10/089,641	Applicant(s) KIM et al.
	Examiner B. Whiteman	Art Unit 1635
<b>NOTICE TO COMPLY WITH REQUIREMENTS FOR PATENT APPLICATIONS CONTAINING NUCLEOTIDE SEQUENCE AND/OR AMINO ACID SEQUENCE DISCLOSURES</b>		
Applicant must file the items indicated below within the time period set in the Office action to which the Notice is attached to avoid abandonment under 35 U.S.C. § 133 (extensions of time may be obtained under the provisions of 37 CFR 1.136(a)).		
The nucleotide and/or amino acid sequence disclosure contained in this application does not comply with the requirements for such a disclosure as set forth in 37 C.F.R. 1.821 - 1.825 for the following reason(s):		
<input checked="" type="checkbox"/> 1. This application clearly fails to comply with the requirements of 37 C.F.R. 1.821-1.825. Applicant's attention is directed to the final rulemaking notice published at 55 FR 18230 (May 1, 1990), and 1114 OG 29 (May 15, 1990). If the effective filing date is on or after July 1, 1998, see the final rulemaking notice published at 63 FR 29620 (June 1, 1998) and 1211 OG 82 (June 23, 1998).		
<input type="checkbox"/> 2. This application does not contain, as a separate part of the disclosure on paper copy, a "Sequence Listing" as required by 37 C.F.R. 1.821(c).		
<input type="checkbox"/> 3. A copy of the "Sequence Listing" in computer readable form has not been submitted as required by 37 C.F.R. 1.821(e).		
<input type="checkbox"/> 4. A copy of the "Sequence Listing" in computer readable form has been submitted. However, the content of the computer readable form does not comply with the requirements of 37 C.F.R. 1.822 and/or 1.823, as indicated on the attached copy of the marked -up "Raw Sequence Listing."		
<input type="checkbox"/> 5. The computer readable form that has been filed with this application has been found to be damaged and/or unreadable as indicated on the attached CRF Diskette Problem Report. A Substitute computer readable form must be submitted as required by 37 C.F.R. 1.825(d).		
<input type="checkbox"/> 6. The paper copy of the "Sequence Listing" is not the same as the computer readable from of the "Sequence Listing" as required by 37 C.F.R. 1.821(e).		
<input checked="" type="checkbox"/> 7. Other: See Raw sequence listing error report.		
<b>Applicant Must Provide:</b>		
<input checked="" type="checkbox"/> An initial or <u>substitute</u> computer readable form (CRF) copy of the "Sequence Listing".		
<input checked="" type="checkbox"/> An initial or <u>substitute</u> paper copy of the "Sequence Listing", as well as an amendment specifically directing its entry into the specification.		
<input checked="" type="checkbox"/> A statement that the content of the paper and computer readable copies are the same and, where applicable, include no new matter, as required by 37 C.F.R. 1.821(e) or 1.821(f) or 1.821(g) or 1.825(b) or 1.825(d).		
For questions regarding compliance to these requirements, please contact:		
For Rules Interpretation, call (571) 272-2510		
For CRF Submission Help, call (571) 272-2501/2583.		
PatentIn Software Program Support		
Technical Assistance.....703-287-0200		
To Purchase PatentIn Software.....703-306-2600		
<b>PLEASE RETURN A COPY OF THIS NOTICE WITH YOUR REPLY</b>		

BRIAN WHITEMAN  
PATENT EXAMINER

Dn 1/4